IFNB1 / IFN-beta / Interferon beta Protein

Interferon beta

IFN beta / IFNB Products

IFN beta / IFNB Protein, Recombinant

Molecule	Species	Description	Cat. No
IFN beta/IFNB	Human	IFN beta/IFNB/Fc Protein, Recombinant	10704-H02H
IFN beta/IFNB	Human	IFN beta/IFNB Protein, Recombinant	10704-HNAC
IFN beta/IFNB	Mouse	IFNB1 / IFN-beta / Interferon beta Protein, Recombinant	50708-M02H

  10704-H02H: The EC₅₀ for this effect is 0.75 ng/mL. Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV).

  10704-HNAC: The EC₅₀ for this effect is typically 10-50 pg/mL. Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV).

IFN beta / IFNB Antibody

Molecule	Application	Description	Cat. No
Human IFN beta/IFNB	WB, ELISA	Mouse Monoclonal Antibody	10704-MM01

IFNB1 cDNA Clone

Molecule	Species	Description	Cat. No
IFNB1	Mouse	IFNB1 cDNA Clone / ORF Clone	MG50708-M
IFNB1	Rat	Rat IFNB1 cDNA Clone / ORF Clone	RG80172-G
IFNB1	Cynomolgus	Cynomolgus monkey IFNB1 cDNA Clone / ORF Clone	KG90104-G

IFN beta / IFNB Related Areas

Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IFN beta/IFNB

Immunology>>Cytokine & Receptor>>Interleukin & Receptor >>IL-10/Interferon Family>>IFN beta/IFNB

IFN beta / IFNB Alternative Names

IFN beta, IFNB [Homo sapiens]

IFN beta, Ifnb1, RP23-19G2.2, IFNB, Ifb [Mus musculus]

IFN beta / IFNB Background

Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. Interferon-beta (IFN beta) is an extra-cellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or cause autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of a chronic progressive CNS inflammation.

IFN beta / IFNB Related Studies

1. Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
2. Stübgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
3. Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.